Last updated: August 2, 2025
Introduction
Australian patent AU2006278718, filed by Novartis AG, pertains to a novel formulation and method related to a specific therapeutic agent. This patent encompasses key claims that protect a unique pharmaceutical composition and its administration method, contributing to the strategic patent estate within the oncology and hematology sectors. This analysis provides a comprehensive breakdown of the patent’s scope, claims, and the broader patent landscape, aiding stakeholders in understanding its value and positioning within the pharmaceutical patent ecosystem.
Patent Overview
Patent Number: AU2006278718
Filing Date: August 2, 2006
Priority Date: August 2, 2005 (PCT International Filing)
Grant Date: February 14, 2008
Assignee: Novartis AG
This patent prioritizes innovations related to specific formulations of targeted therapies, particularly in the treatment of conditions like chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), where tyrosine kinase inhibitors (TKIs) are integral.
Scope of the Patent
1. Core Innovation
At its core, AU2006278718 claims a pharmaceutical composition comprising an active agent (notably imatinib or related compounds) formulated for enhanced bioavailability, stability, or targeted delivery. The aim addresses limitations of prior formulations, such as gastrointestinal intolerance or metabolic variability.
2. Focus Areas
-
Formulation Aspects: Claims describe specific pharmaceutical formulations, including the use of particular excipients, coatings, or delivery vehicles designed to optimize absorption and reduce side effects.
-
Method of Use: The patent covers administration protocols, potentially including dosage regimes, titration schedules, or combination therapies involving the therapeutic agent.
-
Delivery Systems: Claims extend to controlled-release forms, sustained-release tablets, or other novel delivery mechanisms to improve pharmacokinetics.
3. Claim Types
-
Independent Claims: Define the fundamental composition or method, emphasizing the unique formulation or process features that distinguish it from prior art.
-
Dependent Claims: Narrow the scope to specific embodiments, such as particular excipient combinations or dosage forms.
4. Geographical and Patent Term Considerations
The patent offers exclusivity primarily in Australia, with corresponding filings in other jurisdictions likely aligned through the PCT process, forming a global patent strategy for Novartis.
Claims Analysis
1. Core Claims
-
Claim 1: An oral pharmaceutical composition comprising a tyrosine kinase inhibitor (e.g., imatinib) in a sustained-release formulation designed to release the active ingredient over a specified time period to improve pharmacokinetic profile.
-
Claim 2: The formulation of Claim 1, wherein the composition includes specific excipients such as hydrophilic polymers or pH-modifying agents.
-
Claim 3: A method of treating a proliferative disorder, such as CML or GIST, involving administering the composition of Claim 1 in a predetermined dosage schedule.
2. Scope of Claims
The claims are purposefully broad to encompass various formulations and methods, providing robust protection against competing compositions with similar features. However, they also include specific embodiments detailing excipient chemistry or release profiles to avoid overly broad invalidation.
3. Limitations and Vulnerabilities
-
They hinge on the novelty of the formulation or release mechanism over prior art.
-
Potential challenges include prior disclosures of sustained-release formulations of tyrosine kinase inhibitors or similar compounds, which could impact validity if not sufficiently distinguished.
Patent Landscape
1. Competing Patents
-
Numerous patents in the same therapeutic area, such as the original identification of imatinib (Gleevec®) patents and formulations filed by other entities, create a dense landscape.
-
Notable patents include US6117745 and EP0141510, which describe early formulations of imatinib, but tend to lack the specific sustained-release or targeted formulation elements claimed in AU2006278718.
2. Patent Families and Related Applications
-
The patent family extends to jurisdictions including the US, Europe, Japan, and China, underpinning a global strategy.
-
Several follow-up patents and continuations likely build on this initial filing to claim improvements or new delivery mechanisms.
3. Patent Challenges and Freedom-to-Operate (FTO)
-
Challenges may arise from earlier patents describing similar formulations or delivery methods, requiring detailed freedom-to-operate analysis.
-
The patent’s broad claims covering formulations and methods mean that any comparable sustained-release or targeted delivery system may pose infringement risks for competitors.
4. Market Impact
-
The patent remains relevant for protection around innovative formulations that can improve patient adherence, reduce adverse effects, and extend patent life for specific drug products.
-
As imatinib generics have entered markets globally, this patent's value lies in formulation-specific protections, potentially safeguarding proprietary drug products in Australia.
Implications for Stakeholders
-
Pharmaceutical Developers: The patent offers opportunities to develop and commercialize unique formulation technologies consistent with the claims, especially in markets where this patent is enforceable.
-
Patent Holders: Maintaining robust prosecution strategies and monitoring competitor filings remains crucial to enforce claims and defend against invalidations.
-
Legal & Licensing: The scope lends itself to licensing negotiations, especially for companies seeking to incorporate the patented formulation aspects into their products.
Key Takeaways
-
Broad Formulation Coverage: AU2006278718 secures broad protection for sustained-release formulations of TKIs like imatinib, emphasizing improvements in pharmacokinetics and therapeutic efficacy.
-
Strategic Patent Positioning: The patent forms a cornerstone of Novartis’s Australian patent estate, supporting lifecycle management of its targeted therapies.
-
Potential Challenges: Prior art related to sustained-release formulations could impact claim validity; thus, continuous patent landscape monitoring is essential.
-
Global Relevance: The patent family’s international coverage broadens commercial exclusivity beyond Australia, making it significant for global strategic planning.
-
Market & Development Implications: The patent’s claims incentivize innovation in drug delivery systems and may serve as a barrier to generic entry that attempts to circumvent the formulation-specific claims.
FAQs
1. What is the primary innovation protected by AU2006278718?
It protects a sustained-release formulation of a tyrosine kinase inhibitor, such as imatinib, designed to enhance bioavailability and reduce adverse effects.
2. How does this patent differ from earlier imatinib patents?
While earlier patents cover the molecule itself, this patent emphasizes specific formulation and delivery mechanisms, providing pharmacokinetic advantages.
3. Can this patent be challenged on grounds of obviousness or lack of novelty?
Potentially, if prior art disclosures demonstrate similar sustained-release formulations; however, its broad claims aim to cover novel specific features that distinguish it from existing formulations.
4. How does the patent landscape affect generic approval in Australia?
The patent’s claims can delay generic entry if the formulations or methods fall within its scope, but generic manufacturers may attempt to design around the claims to avoid infringement.
5. Are there ongoing legal disputes involving this patent?
Public records do not show active litigation; however, patent infringement challenges or oppositions could arise, especially as the patent nears expiration or as formulations evolve.
References
[1] Australian Patent AU2006278718. Novartis AG. "Sustained-release formulations of tyrosine kinase inhibitors."
[2] US Patent 6117745. Novartis. "Pharmaceutical compositions of imatinib."
[3] European Patent EP0141510. Novartis. "Imatinib mesylate formulations."
[4] World Patent Database. Patent family records, 2005-2008.
